Beranda › Penyakit Alzheimer › Arizona
Uji klinis Penyakit Alzheimer di Arizona
23 studi untuk Penyakit Alzheimer mencari peserta di lokasi di Arizona.
Kota di Arizona
Teks studi resmi (Bahasa Inggris)
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
- Clinical Site, Phoenix
- Clinical Site, Scottsdale
- Clinical Site, Tucson
Menerima pesertaFase 2
Usia 55 hingga 90 · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06887192A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
- Local Institution - 2609, Chandler
- Imaging Endpoints, Scottsdale
Menerima pesertaFase 3
Usia 55 hingga 90 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06937229A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
- TrialSphere Corp, Chandler
- HonorHealth Research Institute, Scottsdale
Menerima pesertaFase 2
Usia 55 hingga 85 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07589595A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Gilbert Neurology Partners - PLLC - Avacare, Gilbert
- Banner Alzheimer's Institute, Phoenix
Menerima pesertaFase 3
Usia 55 hingga 90 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06585787Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
- Banner Alzheimer's Institute, Phoenix
- Barrow Neurological Institute, Phoenix
- Clinical Endpoints, Scottsdale
Menerima pesertaFase 2
Usia 55 hingga 80 · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT06847321Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
- Banner Alzheimer?s Institute, Phoenix
- Banner Sun Health Research Institute, Sun City
Menerima pesertaFase 3
Usia 50 hingga 90 · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT07177352A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
- Chandler Clinical Trials, LLC, Chandler
- Local Institution - 2631, Chandler
- TrialSphere Corp, Chandler
Menerima pesertaFase 3
Usia 55 hingga 90 · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07011745A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
- Imaging Endpoints, Scottsdale
Menerima pesertaFase 3
Usia 55 hingga 90 · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07011732Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
- Local Institution - 0040, Scottsdale
Menerima pesertaFase 2
Usia 55 hingga 90 · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT06808984A Study of AMDX-2011P in Participants With Alzheimer's Disease
- Associated Retina Consultants, Phoenix
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Agu 2026 · NCT06514001The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults Study
- University of Arizona, Tucson
Menerima peserta
Usia 55 hingga 85 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT05988385Goal Setting to Promote Physical Activity Adherence in Midlife Adults
- Arizona State University, Phoenix
Menerima pesertaSukarelawan sehat diterima
Usia 45 hingga 65 · Semua jenis kelamin · Diperbarui 17 Jul 2026 · NCT05980052A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
- Banner Alzheimer's Institute, Phoenix
Menerima pesertaFase 3
Usia 55 ke atas · Semua jenis kelamin · Diperbarui 7 Jul 2026 · NCT07602582A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
- Gilbert Neurology Partners/CCT Research, Gilbert
Menerima pesertaFase 3
Usia 55 hingga 90 · Semua jenis kelamin · Diperbarui 30 Jun 2026 · NCT06947941A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
- Banner Alzheimers Institute, Phoenix
Menerima pesertaFase 2
Usia 50 hingga 85 · Semua jenis kelamin · Diperbarui 26 Jun 2026 · NCT07094516[18F]PI-2620 Phase 3 Histopathological Study
- Barrow Neurological Institute, Phoenix
- Banner Sun Health Research Institute, Sun City
Menerima pesertaFase 3
Usia 50 ke atas · Semua jenis kelamin · Diperbarui 22 Mei 2026 · NCT05641688Trial-Ready Cohort-Down Syndrome (TRC-DS)
- Barrow Neurological Institute, Phoenix
Menerima pesertaStudi observasional
Usia 25 hingga 55 · Semua jenis kelamin · Diperbarui 18 Mei 2026 · NCT04165109A SMART Trial of Adaptive Exercises to Optimize Aerobic-Fitness Responses
- Arizona State University, Phoenix
Menerima pesertaSukarelawan sehat diterima
Usia 65 ke atas · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT05877196Early-Stage Partner in Care Living Alone Plus
- Arizona State University, Phoenix
Menerima peserta
Usia 60 ke atas · Semua jenis kelamin · Diperbarui 27 Mar 2026 · NCT06962111Repurposing Siponimod for Alzheimer's Disease
- St. Joseph's Hospital and Medical Center, Phoenix
Menerima pesertaFase 2
Usia 50 hingga 85 · Semua jenis kelamin · Diperbarui 4 Mar 2026 · NCT06639282A Study of Neurodegeneration and Neuronal Fluctuations in Lewy Body Disease and Alzheimer's Disease
- Mayo Clinic Arizona, Scottsdale
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 50 hingga 95 · Semua jenis kelamin · Diperbarui 3 Feb 2026 · NCT06057909Alzheimer's Prevention Registry: A Program to Accelerate Enrollment Into Studies
- Banner Alzheimer's Institute, Phoenix
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 hingga 110 · Semua jenis kelamin · Diperbarui 16 Des 2025 · NCT02022943PROMIS and Mobility Evaluation in Sarcoma Patients
- Mayo Clinic, Phoenix
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Nov 2025 · NCT07227961Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.